These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8950633)

  • 1. New medical therapies for glaucoma.
    Drake MV
    Int Ophthalmol Clin; 1996; 36(2):53-60. PubMed ID: 8950633
    [No Abstract]   [Full Text] [Related]  

  • 2. [Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
    Gebhardt DO
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):275. PubMed ID: 10086159
    [No Abstract]   [Full Text] [Related]  

  • 3. [New drugs in glaucoma therapy].
    Gramer E
    Klin Monbl Augenheilkd; 1998 Jul; 213(1):aA10-2. PubMed ID: 9743931
    [No Abstract]   [Full Text] [Related]  

  • 4. Hypotensive efficacy in primary open-angle glaucoma and ocular hypertension: latanoprost in monotherapy vs timolol and dorzolamide in association.
    Italian Multicentric Open Randomized Study under the aegis of A.I.S.G.: Final Results and Official Report
    Acta Ophthalmol Scand Suppl; 2000; (232):49-50. PubMed ID: 11235535
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological advances in the treatment of glaucoma.
    Serle JB
    Drugs Aging; 1994 Sep; 5(3):156-70. PubMed ID: 7803944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive intraocular pressure lowering effect of various medications with latanoprost.
    O'Connor DJ; Martone JF; Mead A
    Am J Ophthalmol; 2002 Jun; 133(6):836-7. PubMed ID: 12036683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J
    Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
    Maruyama K; Shirato S
    J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
    Hoyng PF; Rasker MT
    Ned Tijdschr Geneeskd; 1998 Sep; 142(39):2138-41. PubMed ID: 9856229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dorzolamide/timolol and latanoprost/timolol fixed combinations on diurnal intraocular pressure control in primary open-angle glaucoma.
    Eren MH; Gungel H; Altan C; Pasaoglu IB; Sabanci S
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):381-6. PubMed ID: 22320418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma.
    Konstas AG; Kozobolis VP; Tersis I; Leech J; Stewart WC
    Eye (Lond); 2003 Jan; 17(1):41-6. PubMed ID: 12579169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of latanoprost 0.005% once daily and its effect on intraocular pressure as primary or adjunctive therapy.
    Smith SL; Sine CS; Pruitt CA; Stewart WC
    J Ocul Pharmacol Ther; 1999 Feb; 15(1):29-39. PubMed ID: 10048345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study.
    Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K
    Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany.
    Kobelt G; Jönsson L; Gerdtham U; Krieglstein GK
    Graefes Arch Clin Exp Ophthalmol; 1998 Nov; 236(11):811-21. PubMed ID: 9825256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The ocular hypotensive effect of the combination of latanoprost with dorzolamide].
    Chiselita D; Apatachioae I; Poiata I
    Oftalmologia; 1999; 46(1):39-45. PubMed ID: 10641085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies.
    Bayer A; Weiler W; Oeverhaus U; Skrotzki FE; Stewart WC;
    J Ocul Pharmacol Ther; 2004 Dec; 20(6):470-8. PubMed ID: 15684807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New developments in drug therapy of glaucoma].
    Pfeiffer N
    Ophthalmologe; 1992 Feb; 89(1):W1-13. PubMed ID: 1349844
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of latanoprost and dorzolamide in the treatment of patients with open angle glaucoma.
    Niazi MK; Raja N
    J Ayub Med Coll Abbottabad; 2004; 16(1):50-3. PubMed ID: 15125183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma.
    Centofanti M; Manni G; Gregori D; Cocco F; Lorenzano D; Bucci MG
    Graefes Arch Clin Exp Ophthalmol; 2000 Apr; 238(4):302-5. PubMed ID: 10853928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.